Fungal infections in neonates: update on prevention and treatment.
Neonates with gastrointestinal diseases and extremely preterm infants are at highest risk for developing invasive fungal infections. Candida species are commensal organisms that colonize skin and mucosal surfaces as well as adhere to catheter surfaces. Due to the immature immune system of neonates including compromise of the developing barrier defenses of the skin or mucosal membranes, Candida can invade into the bloodstream and disseminate, often making these infections difficult to eradicate. Treatment of bloodstream infections uniquely involves both starting antifungal therapy and removing central venous catheters. Liposomal amphotericin formulations and echinochandins are currently being studied in neonates. Prevention for high risk patients is now feasible with fluconazole prophylaxis.
Kaufman
D A
DA
Department of Pediatrics, University of Virginia School of Medicine Charlottesville, VA 22908, USA. dak4r@virginia.edu
D000666:Amphotericin B / Q000627:therapeutic use; D000935:Antifungal Agents / Q000627:therapeutic use*; D002175:Candida / Q000187:drug effects*; D002177:Candidiasis / Q000175:diagnosis / Q000188:drug therapy* / Q000382:microbiology / Q000517:prevention & control*; D004359:Drug Therapy, Combination; D054714:Echinocandins; D015725:Fluconazole / Q000627:therapeutic use*; D005656:Fungal Proteins / Q000627:therapeutic use; D006801:Humans; D007231:Infant, Newborn; D009181:Mycoses / Q000188:drug therapy / Q000517:prevention & control; D010456:Peptides, Cyclic / Q000627:therapeutic use; D016896:Treatment Outcome
D000935:Antifungal Agents; D054714:Echinocandins; D005656:Fungal Proteins; D010456:Peptides, Cyclic; C068538:liposomal amphotericin B; D000666:Amphotericin B; D015725:Fluconazole; C007572:echinocandin B